Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients

about

Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients

Item

http://www.wikidata.org/entity/Q36158135

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Darunavir and ritonavir total ...... e in HIV-monoinfected patients

@ast

Darunavir and ritonavir total ...... e in HIV-monoinfected patients

@en

type

Item

label

Darunavir and ritonavir total ...... e in HIV-monoinfected patients

@ast

Darunavir and ritonavir total ...... e in HIV-monoinfected patients

@en

prefLabel

Darunavir and ritonavir total ...... e in HIV-monoinfected patients

@ast

Darunavir and ritonavir total ...... e in HIV-monoinfected patients

@en

P1476

Darunavir and ritonavir total ...... e in HIV-monoinfected patients

@en

P2093

Manel Crespo

http://www.w3.org/2001/XMLSchema#string

Mercè Pérez

http://www.w3.org/2001/XMLSchema#string

Rosa María López

http://www.w3.org/2001/XMLSchema#string

P2860

Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.

Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997-2010.

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.

An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection.

Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis

Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV

Liver toxicity in HIV-infected patients receiving novel second-generation nonnucleoside reverse transcriptase inhibitors etravirine and rilpivirine.

P304

6782-6790

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01099-15

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26282411

http://www.w3.org/2001/XMLSchema#string

P932

4604348

http://www.w3.org/2001/XMLSchema#string